P/E ratio for iBio (IBIO)
P/E ratio as of May 2024 (TTM): -0.2546
According to iBio's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.254573. At the end of 2022 the company had a P/E ratio of -0.0498.
P/E ratio history for iBio from 2008 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0498 | -98.77% |
| 2021 | -4.05 | -32.2% |
| 2020 | -5.98 | 3126.68% |
| 2019 | -0.1852 | -69.88% |
| 2018 | -0.6148 | -39.55% |
| 2017 | -1.02 | -64.41% |
| 2016 | -2.86 | -54.08% |
| 2015 | -6.22 | -27.86% |
| 2014 | -8.63 | 128.31% |
| 2013 | -3.78 | -8.6% |
| 2012 | -4.13 | -15.34% |
| 2011 | -4.88 | -38.2% |
| 2010 | -7.90 | -12.22% |
| 2009 | -9.00 | 869.13% |
| 2008 | -0.9287 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.6 | -4,281.00% | 🇺🇸 USA |
 Genocea Biosciences
GNCA | -0.0002 | -99.92% | 🇺🇸 USA |
 Nektar Therapeutics
NKTR | -1.02 | 302.45% | 🇺🇸 USA |
 Emergent BioSolutions
EBS | -0.2732 | 7.31% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.